Implantation of everolimus‐eluting bioresorbable scaffolds in a diabetic all‐comers population

By  

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol. 86, Iss. 6, 2015-11 ,pp. : 975-981

John Wiley & Sons Inc

Access to resources Recommend Favorite

Risk and timing of clinical events according to diabetic status of patients treated with everolimus‐eluting bioresorbable vascular scaffolds versus everolimus‐eluting stent: 2‐year results from a propensity score matched comparison of ABSORB EXTEND and SPIRIT trials

By  

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol. 91, Iss. 3, 2018-02 ,pp. : 387-395

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical outcomes of overlapping versus non‐overlapping everolimus‐eluting absorb bioresorbable vascular scaffolds: An analysis from the multicentre prospective RAI registry (ClinicalTrials.gov identifier: NCT02298413)

By  

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol. 91, Iss. 1, 2018-01 ,pp. : E1-E16

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparison of 2‐year outcomes between zotarolimus‐eluting and everolimus‐eluting new‐generation cobalt–chromium alloy stents in real‐world diabetic patients

By  

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol. 86, Iss. 1, 2015-07 ,pp. : E11-E18

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rationale and design of amphilimus sirolimus‐eluting stents versus zotarolimus‐eluting stents in all‐comers requiring percutaneous coronary intervention (ReCre8): A multicenter randomized clinical trial

By  

CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, Vol. 91, Iss. 3, 2018-02 ,pp. : 410-416

John Wiley & Sons Inc

Access to resources Recommend Favorite